Brown fat is once again providing clues in how to treat metabolic disorders like diabetes. A group of investigators at the University of Michigan followed up on earlier studies that have examined the role of brown fat in burning calories. Their work led them to NRG4, a hormone secreted by brown fat that may play a role as a messenger with the liver in regulating the conversion of sugar into fat, according to the university.
Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France's Servier.
For another clue to the unrest on Sanofi's board, take a look at the third-quarter earnings report. There's not much red ink on the page, that's true: Sales are up 4%. Earnings up 8%. CEO Chris Viehbacher's growth platforms surged by 10%. The trouble lies in Viehbacher's canned quote.
Virginia's Health Diagnostic Laboratory and the University of Utah are zeroing in on fasting levels of simple blood biomarkers that may enable quicker diagnosis of diabetes risks than current standards of care.
Plenty of drugmakers are chasing opportunity in diabetes. The fast-growing epidemic means new therapies are sorely needed. But dealing with diabetes directly isn't the only strategy. Regeneron figures it can score by treating some of the disease's long-term complications.
Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.
Among all the pharma companies, Novo Nordisk always stood out for its relentless R&D focus on diabetes and obesity. Today, the Danish company amped up that concentration another notch, jettisoning a group of clinical programs and winding down its work in anti-inflammatory treatments. And the pharma player added that the move would hit some 400 staffers, with close to half likely to lose their jobs at Novo.
Merck's America's Diabetes Challenge: Get to Your Goals campaign is aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck is launching a similar campaign aimed at the Hispanic community, which is disproportionately affected by the disease.
Scientists have linked a single enzyme to the development of diabetes, a finding that could help develop new treatments for the more than 120 million Americans that have diabetes or pre-diabetes.
Without the safety concerns that plague its competitors, Jardiance may be able to make a splash.